Skip to main content
OCULAR THERAPEUTIX, INC logo

OCULAR THERAPEUTIX, INC — Investor Relations & Filings

Ticker · OCUL ISIN · US67576A1007 LEI · 529900ABAWFXOHSIHG03 US Manufacturing
Filings indexed 801 across all filing types
Latest filing 2025-11-07 Director's Dealing
Country US United States of America
Listing US OCUL

About OCULAR THERAPEUTIX, INC

https://www.ocutx.com/

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of therapies for diseases and conditions of the eye. The company's primary focus is on transforming the treatment of retinal diseases, such as wet age-related macular degeneration (wet AMD), a leading cause of blindness. Ocular Therapeutix utilizes its proprietary hydrogel-based drug delivery platform, ELUTYX™, to develop sustained-release therapies. This technology is designed to reduce the therapeutic burden on patients by decreasing the frequency of required treatments. The company's lead product candidate, AXPAXLI™ (axitinib intravitreal implant), is in late-stage clinical development for major retinal diseases.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2025-11-07 English
Regulatory Filings 2025
Regulatory Filings
2025-11-05 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-05 English
10-Q - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
Interim / Quarterly Report
2025-11-04 English
8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC by Ocular Therapeutix, Inc. dated November 4, 2025. It announces the financial results for the quarter ended September 30, 2025, and includes a press release as Exhibit 99.1. The text explicitly states that the press release is furnished as an exhibit and incorporated by reference, and the Form 8-K itself is a current report, not the full quarterly report. The document length is under 5,000 characters and primarily serves as an announcement of financial results rather than containing detailed financial statements or substantive analysis. According to the classification rules, such a document announcing quarterly financial results is best classified as an Earnings Release (ER).
2025-11-04 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-10-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.